The Ethanol Extract of Evodiae Fructus and Its Ingredient, Rutaecarpine, Inhibit Infection of SARS-CoV-2 and Inflammatory Responses

Int J Mol Sci. 2023 Jan 1;24(1):762. doi: 10.3390/ijms24010762.

Abstract

COVID-19, derived from SARS-CoV-2, has resulted in millions of deaths and caused unprecedented socioeconomic damage since its outbreak in 2019. Although the vaccines developed against SARS-CoV-2 provide some protection, they have unexpected side effects in some people. Furthermore, new viral mutations reduce the effectiveness of the current vaccines. Thus, there is still an urgent need to develop potent non-vaccine therapeutics against this infectious disease. We recently established a series of detecting platforms to screen a large library of Chinese medicinal herbs and phytochemicals. Here, we reveal that the ethanolic extract of Evodiae Fructus and one of its components, rutaecarpine, showed promising potency in inhibiting the activity of 3C-like (3CL) protease, blocking the entry of the pseudo-typed SARS-CoV-2 (including wild-type and omicron) into cultured cells. In addition, inflammatory responses induced by pseudo-typed SARS-CoV-2 were markedly reduced by Evodiae Fructus extract and rutaecarpine. Together our data indicate that the herbal extract of Evodiae Fructus and rutaecarpine are potent anti-SARS-CoV-2 agents, which might be considered as a treatment against COVID-19 in clinical applications.

Keywords: 3CL protease; S-protein ELISA; SARS-CoV-2; anti-inflammatory; cytokines; natural products; traditional Chinese medicine.

MeSH terms

  • COVID-19*
  • Drugs, Chinese Herbal* / pharmacology
  • Evodia*
  • Humans
  • Plant Extracts / pharmacology
  • SARS-CoV-2

Substances

  • rutecarpine
  • Drugs, Chinese Herbal
  • Plant Extracts